ChineseBack to the old website

Homepage News & Trends

News Reports

Chinese Society of Toxicology has established the Specialty Committee of ToxicologySafety Evaluation of Biotechnological Drugs (TSEBD) & The First Academic Conference of the Committee of TSEBD of CST Successfully Held in Chengdu
Publisher:CST Date:2020-12-03 10:34:42

Chinese Society of Toxicology has established the Specialty Committee of Toxicology and Safety Evaluation of Biotechnological Drugs (TSEBD) in Chengdu new drug safety evaluation center, Sichuan University. The Committee founding meeting and the first academic conference of the committee on toxicology and safety evaluation of biotechnological drugs of Chinese society of toxicology (CST) was successfully held from November 11 to 13, 2020 in Chengdu, Sichuan Province. The conference was hosted by the committee of toxicology and safety evaluation of biotechnology drugs of CST and WestChina-Frontier Pharmaceutical Technology Co., Ltd. and Bio-Industry Expert Association of Chengdu hi-tech Zone were the co-organizers. More than 500 participants, including academicians, experts, organization representatives and enterprise representatives from the pharmaceutical field, attended this national toxicology event.

At the founding meeting of the Committee on toxicology and safety evaluation of biotechnological drugs of CST on November 11, the first committee members, standing committee members and leading organization were elected. Cen Xiaobo, professor of West China Hospital of Sichuan University and director of Chengdu new drug safety evaluation center, was elected as the chairman.

On November 12, the first academic conference on toxicology and safety evaluation of biotechnological drugs in 2020 was solemnly opened in Wangjiang Hotel, Chengdu. Scholars, entrepreneurs and people from all walks of life gathered together at the opening ceremony where professor Cen Xiaobo delivered a speech as host.  He said in the speech that the committee on toxicology and safety evaluation of biotechnological drugs is founded under the background that global biotechnology is being developed vigorously and the biotechnology drugs are continuously emerged, the committee will build a professional academic exchange platform for drug safety evaluation and scientific supervision.

Shen Jianzhong, deputy director of China Biotechnology Development Center, Zhou Ping-Kun, president of Chinese Society of Toxicology and professor of the Academy of Military Medical Science, Tian Yunhui, deputy director general of Sichuan Provincial Science and Technology Department, and professor Wang Li, president of WestChina-Frontier Pharmaceutical Technology Co., Ltd, delivered speeches respectively at the opening ceremony.

Academicians Wei Yuquan and Zhang Xingdong of Sichuan University, professor Yuan Bojun of Naval Military Medical University and professor Liao Mingyang of Military Medical Research Institute attended the opening ceremony of the conference.

All the distinguished guests congratulated the successful opening of the conference and expressed their concerns about the safety of biotech drugs. They hoped that with the help of the conference, the national counterparts in the research and development of biotechnological drugs could be gathered together to conduct in-depth discussion on the safety issues in the process of biopharmaceutical and biotechnology research and development, and to provide suggestions for the establishment of a standardized, scientific and modern safety evaluation system for biotechnological drugs.

In the plenary lectures part, academician Wei Yuquan shared the research progress of biotherapy and biotechnological drugs and academician Zhang Xingdong made a sharing report on the topic of biocompatibility evaluation of innovative medical devices. Professor Cen Xiaobo elaborated on the current situation and challenges of non-clinical research evaluation of biotechnology drugs. Dr. Lu Xianping, president of Shenzhen microchip Biotechnology Co., Ltd., shared an integrated platform for drug discovery and early evaluation based on chemical genomics.

Three sub topic reports meetings were held on the afternoon of 12th and 13th of November. The reporting experts conducted in-depth academic exchanges on the current situation, problems and future challenges of non-clinical safety evaluation of biotech drugs and how to promote the clinical transformation of biotech drugs.

During the two-day academic conference, the participating experts shared 23 academic reports, involving safety evaluation, immunogenicity research, analysis and testing of a variety of biotechnology drugs (such as oligonucleotide drugs, oncolytic virus, double antibody, ADC and other drugs) as well as prospective model animal research and development, organoids research and so on.


Prof. Ping-Kun Zhou, President of Chinese Society of Toxicology presents the certificate of committee chairman to Prof. Xiaobo Cen.


Opening ceremony addresses by Shen Jianzhong, deputy director of China Biotechnology Development Center; Zhou Ping-Kun, president of Chinese Society of Toxicology; Tian Yunhui, deputy director general of Sichuan Provincial Science and Technology Department; professor Wang Li, president of WestChina-Frontier Pharmaceutical Technology Co., Ltd.


Academician, Prof. Wei Yuquan gave the plenary lecture 


Academician, Prof. Zhang Xingdong gave the plenary lecture